A review on recent developments of indole-containing antiviral agents

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 421-441

  Zhang, Ming Zhi ^a   Chen, Qiong ^a   Yang, Guang Fu ^a,b  

^a CENTRAL CHINA NORMAL UNIVERSITY   (China)

^b SynBio Research Platform   (China)

Author keywords

Antiviral activity; Entry and fusion inhibitor; Indole; Integrase inhibitor; Natural product; Polymerase inhibitor; Protease inhibitor; Reverse transcriptase inhibitor

Indexed keywords

ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDOLE DERIVATIVE; INDOLYLARYLSULFONE DERIVATIVE; INTEGRASE INHIBITOR; NATURAL PRODUCT; POLYMERASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DEVELOPMENT; DRUG MARKETING; DRUG STRUCTURE; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PROCEDURES; STRUCTURE ACTIVITY RELATION; TRENDS;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; INDOLES; MOLECULAR STRUCTURE; PRODUCT SURVEILLANCE, POSTMARKETING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84908364564     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.065     Document Type: Review

References (125)

1. S. Samala, R.K. Arigela, R. Kant, B. Kundu, Diversity-oriented synthesis of ketoindoloquinoxalines and indolotriazoloquinoxalines from 1-(2-nitroaryl)- 2-alkynylindoles, J. Org. Chem. 79 (2014) 2491-2500.
2. C. Won, X. Shen, K. Mashiguchi, Z. Zheng, X. Dai, Y. Cheng, H. Kasahara, Y. Kamiya, J. Chory, Y. Zhao, Conversion of tryptophan to indole-3-acetic acid by TRYPTOPHAN AMINOTRANSFERASES OF ARABIDOPSIS and YUCCAs in Arabidopsis, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 18518-18523.
3. M.Z. Zhang, N. Mulholland, D. Beattie, D. Irwin, Y.C. Gu, Q. Chen, G.F. Yang, J. Clough, Synthesis and antifungal activity of 3-(1,3,4-oxadiazol-5-yl)-indoles and 3-(1,3,4-oxadiazol-5-yl)methyl-indoles, Eur. J. Med. Chem. 63 (2013) 22-32.
4. S.N. Young, How to increase serotonin in the human brain without drugs, J. Psychiatry Neurosci. 32 (2007) 394-399.
5. L.B. Diss, S.D. Robinson, Y. Wu, S. Fidalgo, M.S. Yeoman, B.A. Patel, Agerelated changes in melatonin release in the murine distal colon, ACS Chem. Neurosci. 4 (2013) 879-887.
6. S.A. Patil, R. Patil, D.D. Miller, Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents, Future Med. Chem. 4 (2012) 2085-2115.
7. J.V. Higdon, B. Delage, D.E. Williams, R.H. Dashwood, Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis, Pharmacol. Res. 55 (2007) 224-236.
8. E.G. Rogan, The natural chemopreventive compound indole-3-carbinol: state of the science, In Vivo 20 (2006) 221-228.
9. Y.S. Kim, J.A. Milner, Targets for indole-3-carbinol in cancer prevention, J. Nutr. Biochem. 16 (2005) 65-73.
10. B. Biersack, R. Schobert, Indole compounds against breast cancer: recent developments, Curr. Drug Targets 13 (2012) 1705-1719.
11. W.G. Kurz, K.B. Chatson, F. Constabel, J.P. Kutney, L.S. Choi, P. Kolodziejczyk, S.K. Sleigh, K.L. Stuart, B.R. Worth, Alkaloid Production in Catharanthus roseus cell cultures VIII, Planta Med. 42 (1981) 22-31.
12. F. Leon, E. Habib, J.E. Adkins, E.B. Furr, C.R. McCurdy, S.J. Cutler, Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A, Nat. Prod. Commun. 4 (2009) 907-910.
13. F.-E. Chen, J. Huang, Reserpine: a Challenge for total synthesis of natural products, Chem. Rev. 105 (2005) 4671-4706.
14. H. Ishikawa, D.A. Colby, D.L. Boger, Direct coupling of catharanthine and vindoline to provide vinblastine: total synthesis of (+)- and ent- (-)-vinblastine, J. Am. Chem. Soc. 130 (2008) 420-421.
15. F.R. deSa Alves, E.J. Barreiro, C.A. Fraga, Fromnature todrugdiscovery: the indole scaffold as a 'privileged structure', Mini Rev. Med. Chem. 9 (2009) 782-793.
16. B.E. Evans, K.E. Rittle, M.G. Bock, R.M. DiPardo, R.M. Freidinger, W.L. Whitter, G.F. Lundell, D.F. Veber, P.S. Anderson, R.S. Chang, V.J. Lotti, D.J. Cerino, T.B. Chen, P.J. Kling, K.A. Kunkel, J.P. Springer, J. Hirshfield, Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists, J. Med. Chem. 31 (1988) 2235-2246.
17. M.E. Welsch, S.A. Snyder, B.R. Stockwell, Privileged scaffolds for library design and drug discovery, Curr. Opin. Chem. Biol. 14 (2010) 347-361.
18. N.K. Kaushik, N. Kaushik, P. Attri, N. Kumar, C.H. Kim, A.K. Verma, E.H. Choi, Biomedical importance of indoles, Molecules 18 (2013) 6620-6662.
19. R.E. Dolle, K.H. Nelson Jr., Comprehensive survey of combinatorial library synthesis: 1998, J. Comb. Chem. 1 (1999) 235-282.
20. R.G. Franzen, Recent advances in the preparation of heterocycles on solid support: a review of the literature, J. Comb. Chem. 2 (2000) 195-214.
21. R.E. Dolle, Comprehensive survey of combinatorial library synthesis: 2000, J. Comb. Chem. 3 (2001) 477-517.
22. E.A.I.E. Vitaku, J.T. Njardarson, Compiled and Produced by the Njardarson Group (The University of Arizona), 2013. http://cbc.arizona.edu/njardarson/group/top-pharmaceuticals-poster.
23. A. Daugan, P. Grondin, C. Ruault, A.C. Le Monnier de Gouville, H. Coste, J.M. Linget, J. Kirilovsky, F. Hyafil, R. Labaudiniere, The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino [1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues, J. Med. Chem. 46 (2003) 4533-4542.
24. A. Daugan, P. Grondin, C. Ruault, A.C. Le Monnier de Gouville, H. Coste, J. Kirilovsky, F. Hyafil, R. Labaudiniere, The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1′,5′: 1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues, J. Med. Chem. 46 (2003) 4525-4532.
25. H. Xu, M. Lv, Developments of indoles as anti-HIV-1 inhibitors, Curr. Pharm. Des. 15 (2009) 2120-2148.
26. S. Olgen, Recent development of new substituted indole and azaindole derivatives as anti-HIV agents, Mini Rev. Med. Chem. 13 (2013) 1700-1708.
27. I.A. Leneva, R.J. Russell, Y.S. Boriskin, A.J. Hay, Characteristics of arbidolresistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol, Antiviral Res. 81 (2009) 132-140.
28. Y.S. Boriskin, I.A. Leneva, E.I. Pecheur, S.J. Polyak, Arbidol: a broad-spectrum antiviral compound that blocks viral fusion, Curr. Med. Chem. 15 (2008) 997-1005.
29. F. Zhang, G. Wang, A review of non-nucleoside anti-hepatitis B virus agents, Eur. J. Med. Chem. 75 (2014) 267-281.
30. E.I. Pecheur, D. Lavillette, F. Alcaras, J. Molle, Y.S. Boriskin, M. Roberts, F.L. Cosset, S.J. Polyak, Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol, Biochemistry 46 (2007) 6050-6059.
31. J. Villalain, Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes, J. Phys. Chem. B 114 (2010) 8544-8554.
32. D.L. Romero, R.A. Olmsted, T.J. Poel, R.A. Morge, C. Biles, B.J. Keiser, L.A. Kopta, J.M. Friis, J.D. Hosley, K.J. Stefanski, D.G. Wishka, D.B. Evans, J. Morris, R.G. Stehle, S.K. Sharma, Y. Yagi, R.L. Voorman, W.J. Adams, W.G. Tarpley, R.C. Thomas, Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors, J. Med. Chem. 39 (1996) 3769-3789.
33. J. Mannu, P. Jenardhanan, P.P. Mathur, A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs, J. Mol. Model 17 (2011) 1847-1854.
34. G.D. Morse, R.C. Reichman, M.A. Fischl, M. Para, J. Leedom, W. Powderly, L.M. Demeter, L. Resnick, Y. Bassiakos, J. Timpone, S. Cox, D. Batts, Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams, Antiviral Res. 45 (2000) 47-58.
35. A.M. Been-Tiktak, H.M. Vrehen, M.M. Schneider, M. van der Feltz, T. Branger, P. Ward, S.R. Cox, J.D. Harry, J.C. Borleffs, Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients, Antimicrob. Agents Chemother. 39 (1995) 602-607.
36. X.J. Zhou, K. Pietropaolo, D. Damphousse, B. Belanger, J. Chen, J. Sullivan-Bolyai, D. Mayers, Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects, Antimicrob. Agents Chemother. 53 (2009) 1739-1746.
37. S. Castellino, M.R. Groseclose, J. Sigafoos, D. Wagner, M. de Serres, J.W. Polli, E. Romach, J. Myer, B. Hamilton, Central nervous system disposition and metabolism of Fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: an LC-MS and Matrix-assisted laser desorption/ionization imaging MS investigation into central nervous system toxicity, Chem. Res. Toxicol. 26 (2013) 241-251.
38. S. Piscitelli, J. Kim, E. Gould, Y. Lou, S. White, M. de Serres, M. Johnson, X.J. Zhou, K. Pietropaolo, D. Mayers, Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor, Br. J. Clin. Pharmacol. 74 (2012) 336-345.
39. D.A. Margolis, J.J. Eron, E. DeJesus, S. White, P. Wannamaker, B. Stancil, M. Johnson, Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761), Antivir. Ther. 19 (2014) 69-78.
40. C. Zala, M. St Clair, K. Dudas, J. Kim, Y. Lou, S. White, S. Piscitelli, E. Dumont, K. Pietropaolo, X.J. Zhou, D. Mayers, Safety and efficacy of GSK2248761, a nextgeneration nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects, Antimicrob. Agents Chemother. 56 (2012) 2570-2575.
41. H. Suzuki, K. Kato, H. Kumagai, Development of an efficient enzymatic production of gamma-D-glutamyl-L-tryptophan (SCV-07), a prospective medicine for tuberculosis, with bacterial gamma-glutamyltranspeptidase, J. Biotechnol. 111 (2004) 291-295.
42. R.J. Aspinall, P.J. Pockros, SCV-07 (SciClone Pharmaceuticals/Verta), Curr. Opin. Investig. Drugs 7 (2006) 180-185.
43. T.A. Rasmussen, O. Schmeltz Sogaard, C. Brinkmann, F. Wightman, S.R. Lewin, J. Melchjorsen, C. Dinarello, L. Ostergaard, M. Tolstrup, Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation, Hum. Vaccin. Immunother. 9 (2013) 993-1001.
44. H.M. Prince, M.J. Bishton, R.W. Johnstone, Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors, Future Oncol. 5 (2009) 601-612.
45. P.L. Beaulieu, M. Bos, M.G. Cordingley, C. Chabot, G. Fazal, M. Garneau, J.R. Gillard, E. Jolicoeur, S. LaPlante, G. McKercher, M. Poirier, M.A. Poupart, Y.S. Tsantrizos, J. Duan, G. Kukolj, Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV), J. Med. Chem. 55 (2012) 7650-7666.
46. R.G. Gentles, M. Ding, J.A. Bender, C.P. Bergstrom, K. Grant-Young, P. Hewawasam, T. Hudyma, S. Martin, A. Nickel, A. Regueiro-Ren, Y. Tu, Z. Yang, K.S. Yeung, X. Zheng, S. Chao, J.H. Sun, B.R. Beno, D.M. Camac, C.H. Chang, M. Gao, P.E. Morin, S. Sheriff, J. Tredup, J. Wan, M.R. Witmer, D. Xie, U. Hanumegowda, J. Knipe, K. Mosure, K.S. Santone, D.D. Parker, X. Zhuo, J. Lemm, M. Liu, L. Pelosi, K. Rigat, S. Voss, Y. Wang, Y.K. Wang, R.J. Colonno, M. Gao, S.B. Roberts, Q. Gao, A. Ng, N.A. Meanwell, J.F. Kadow, Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase, J. Med. Chem. 57 (2014) 1855-1879.
47. C.A. Coburn, P.T. Meinke, W. Chang, C.M. Fandozzi, D.J. Graham, B. Hu, Q. Huang, S. Kargman, J. Kozlowski, R. Liu, J.A. McCauley, A.A. Nomeir, R.M. Soll, J.P. Vacca, D. Wang, H. Wu, B. Zhong, D.B. Olsen, S.W. Ludmerer, Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity, ChemMedChem 8 (2013) 1930-1940.
48. S. Nakamoto, T. Kanda, S. Wu, H. Shirasawa, O. Yokosuka, Hepatitis C virus NS5A inhibitors and drug resistance mutations, World J. Gastroenterol. 20 (2014) 2902-2912.
49. I. Gentile, A.R. Buonomo, E. Zappulo, G. Borgia, Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev. Anti Infect. Ther. 12 (2014) 763-773.
50. F. Yu, L. Lu, L. Du, X. Zhu, A.K. Debnath, S. Jiang, Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket, Viruses 5 (2013) 127-149.
51. B. Devogelaere, J.M. Berke, L. Vijgen, P. Dehertogh, E. Fransen, E. Cleiren, L. van der Helm, O. Nyanguile, A. Tahri, K. Amssoms, O. Lenz, M.D. Cummings, R.F. Clayton, S. Vendeville, P. Raboisson, K.A. Simmen, G.C. Fanning, T.I. Lin, TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage, Antimicrob. Agents Chemother. 56 (2012) 4676-4684.
52. M.D. Cummings, T.I. Lin, L. Hu, A. Tahri, D. McGowan, K. Amssoms, S. Last, B. Devogelaere, M.C. Rouan, L. Vijgen, J.M. Berke, P. Dehertogh, E. Fransen, E. Cleiren, L. van der Helm, G. Fanning, O. Nyanguile, K. Simmen, P. Van Remoortere, P. Raboisson, S. Vendeville, Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase, J. Med. Chem. 57 (2014) 1880-1892.
53. Z. Yang, L. Zadjura, C. D'Arienzo, A. Marino, K. Santone, L. Klunk, D. Greene, P.F. Lin, R. Colonno, T. Wang, N. Meanwell, S. Hansel, Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics, Biopharm. Drug Dispos. 26 (2005) 387-402.
54. P.F. Lin, W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y.F. Gong, H.G. Wang, R. Rose, G. Yamanaka, B. Robinson, C.B. Li, R. Fridell, C. Deminie, G. Demers, Z. Yang, L. Zadjura, N. Meanwell, R. Colonno, A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11013-11018.
55. R.J. Lu, J.A. Tucker, J. Pickens, Y.A. Ma, T. Zinevitch, O. Kirichenko, V. Konoplev, S. Kuznetsova, S. Sviridov, E. Brahmachary, A. Khasanov, C. Mikel, Y. Yang, C. Liu, J. Wang, S. Freel, S. Fisher, A. Sullivan, J. Zhou, S. Stanfield-Oakley, B. Baker, J. Sailstad, M. Greenberg, D. Bolognesi, B. Bray, B. Koszalka, P. Jeffs, C. Jeffries, A. Chucholowski, C. Sexton, Heterobiaryl human immunodeficiency virus entry inhibitors, J. Med. Chem. 52 (2009) 4481-4487.
56. K.S. Yeung, Z. Qiu, Q. Xue, H. Fang, Z. Yang, L. Zadjura, C.J. D'Arienzo, B.J. Eggers, K. Riccardi, P.Y. Shi, Y.F. Gong, M.R. Browning, Q. Gao, S. Hansel, K. Santone, P.F. Lin, N.A. Meanwell, J.F. Kadow, Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agents, Bioorg. Med. Chem. Lett. 23 (2013) 198-202.
57. K.S. Yeung, Z. Qiu, Z. Yin, A. Trehan, H. Fang, B. Pearce, Z. Yang, L. Zadjura, C.J. D'Arienzo, K. Riccardi, P.Y. Shi, T.P. Spicer, Y.F. Gong, M.R. Browning, S. Hansel, K. Santone, J. Barker, T. Coulter, P.F. Lin, N.A. Meanwell, J.F. Kadow, Inhibitors of HIV-1 attachment. Part 8: the effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors, Bioorg. Med. Chem. Lett. 23 (2013) 203-208.
58. K.S. Yeung, Z. Qiu, Z. Yang, L. Zadjura, C.J. D'Arienzo, M.R. Browning, S. Hansel, X.S. Huang, B.J. Eggers, K. Riccardi, P.F. Lin, N.A. Meanwell, J.F. Kadow, Inhibitors of HIV-1 attachment. Part 9: an assessment of oral prodrug approaches to improve the plasma exposure of a tetrazolecontaining derivative, Bioorg. Med. Chem. Lett. 23 (2013) 209-212.
59. A. Balupuri, C.G. Gadhe, P.K. Balasubramanian, G. Kothandan, S.J. Cho, In silico study on indole derivatives as anti HIV-1 agents: a combined docking, molecular dynamics and 3D-QSAR study, Arch. Pharm. Res. 37 (2014) 1001-1015.
60. W.J. Allen, R.C. Rizzo, Computer-aided approaches for targeting HIVgp41, Biol. (Basel) 1 (2012) 311-338.
61. G. Zhou, D. Wu, E. Hermel, E. Balogh, M. Gochin, Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41, Bioorg. Med. Chem. Lett. 20 (2010) 1500-1503.
62. G. Zhou, D. Wu, B. Snyder, R.G. Ptak, H. Kaur, M. Gochin, Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41, J. Med. Chem. 54 (2011) 7220-7231.
63. L.R. Whitby, K.E. Boyle, L. Cai, X. Yu, M. Gochin, D.L. Boger, Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive alpha-helix mimetic library, Bioorg. Med. Chem. Lett. 22 (2012) 2861-2865.
64. S.K. Balani, T.M. Ciccarone, M.E. Goldman, W.J. Greenlee, W.S. Saari, A.D. Theoharides, J.S. Wai, T.M. Williams. Indoles as inhibitors of HIV reverse transcriptase, Patent. WO 1993005020, 1993.
65. T.M. Williams, T.M. Ciccarone, S.C. MacTough, C.S. Rooney, S.K. Balani, J.H. Condra, E.A. Emini, M.E. Goldman, W.J. Greenlee, L.R. Kauffman, J.A. O'Brien, V.V. Sardana, W.A. Schleif, A.D. Theoharides, P.S. Anderson, 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase, J. Med. Chem. 36 (1993) 1291-1294.
66. R. Silvestri, M. Artico, G. De Martino, G. La Regina, R. Loddo, M. La Colla, M. Mura, P. La Colla, Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations, J. Med. Chem. 47 (2004) 3892-3896.
67. G. La Regina, A. Coluccia, A. Brancale, F. Piscitelli, V. Famiglini, S. Cosconati, G. Maga, A. Samuele, E. Gonzalez, B. Clotet, D. Schols, J.A. Este, E. Novellino, R. Silvestri, Newnitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors, J. Med. Chem. 55 (2012) 6634-6638.
68. Z. Zhao, S.E. Wolkenberg, P.E. Sanderson, M. Lu, V. Munshi, G. Moyer, M. Feng, A.V. Carella, L.T. Ecto, L.J. Gabryelski, M.T. Lai, S.G. Prasad, Y. Yan, G.B. McGaughey, M.D. Miller, C.W. Lindsley, G.D. Hartman, J.P. Vacca, T.M. Williams, Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs), Bioorg. Med. Chem. Lett. 18 (2008) 554-559.
69. R. Ragno, M. Artico, G. De Martino, G. La Regina, A. Coluccia, A. Di Pasquali, R. Silvestri, Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives, J. Med. Chem. 48 (2005) 213-223.
70. R. Ragno, A. Coluccia, G. La Regina, G. De Martino, F. Piscitelli, A. Lavecchia, E. Novellino, A. Bergamini, C. Ciaprini, A. Sinistro, G. Maga, E. Crespan, M. Artico, R. Silvestri, Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide, J. Med. Chem. 49 (2006) 3172-3184.
71. G. La Regina, A. Coluccia, A. Brancale, F. Piscitelli, V. Gatti, G. Maga, A. Samuele, C. Pannecouque, D. Schols, J. Balzarini, E. Novellino, R. Silvestri, Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide, J. Med. Chem. 54 (2011) 1587-1598.
72. V. Famiglini, G. La Regina, A. Coluccia, S. Pelliccia, A. Brancale, G. Maga, E. Crespan, R. Badia, B. Clotet, J.A. Este, R. Cirilli, E. Novellino, R. Silvestri, New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors, Eur. J. Med. Chem. 80 (2014) 101-111.
73. R. Storer, F.R. Alexandre, C. Dousson, A.M. Moussa, E. Bridges, A. Stewart, J. Y. Wang, B. A. Mayes. Enantiomerically pure phosphoindoles as HIV inhibitors, Patent. WO 2008042240, 2008.
74. F. Piscitelli, A. Coluccia, A. Brancale, G. La Regina, A. Sansone, C. Giordano, J. Balzarini, G. Maga, S. Zanoli, A. Samuele, R. Cirilli, F. La Torre, A. Lavecchia, E. Novellino, R. Silvestri, Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus, J. Med. Chem. 52 (2009) 1922-1934.
75. F.R. Alexandre, A. Amador, S. Bot, C. Caillet, T. Convard, J. Jakubik, C. Musiu, B. Poddesu, L. Vargiu, M. Liuzzi, A. Roland, M. Seifer, D. Standring, R. Storer, C.B. Dousson, Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors, J. Med. Chem. 54 (2011) 392-395.
76. M. Hassam, A.E. Basson, D.C. Liotta, L. Morris, W.A. van Otterlo, S.C. Pelly, Novel Cyclopropyl-indole derivatives as HIV non-nucleoside reverse transcriptase inhibitors, ACS Med. Chem. Lett. 3 (2012) 470-475.
77. W.G. Lee, R. Gallardo-Macias, K.M. Frey, K.A. Spasov, M. Bollini, K.S. Anderson, W.L. Jorgensen, Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group, J. Am. Chem. Soc. 135 (2013) 16705-16713.
78. X. Han, W. Ouyang, B. Liu, W. Wang, P. Tien, S. Wu, H.B. Zhou, Enantioselective inhibition of reverse transcriptase (RT) of HIV-1 by non-racemic indole-based trifluoropropanoates developed by asymmetric catalysis using recyclable organocatalysts, Org. Biomol. Chem. 11 (2013) 8463-8475.
79. S.C. Ashok Penta, S. Ganguly, De novo design and in-silico studies of novel 1-phenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole -3-carboxylic acid derivatives as HIV-1 reverse transcriptase inhibitors, Med. Chem. Res. 23 (2014) 3662-3670.
80. H. Xu, W.Q. Liu, L.L. Fan, Y. Chen, L.M. Yang, L. Lv, Y.T. Zheng, Synthesis and HIV-1 integrase inhibition activity of some N-arylindoles, Chem. Pharm. Bull. 56 (2008) 720-722.
81. S.V. Jain, L.V. Sonawane, R.R. Patil, S.B. Bari, Pharmacophore modeling of some novel indole β-diketo acid and coumarin-based derivatives as HIV integrase inhibitors, Med. Chem. Res. 21 (2012) 165-173.
82. Y. Goldgur, R. Craigie, G.H. Cohen, T. Fujiwara, T. Yoshinaga, T. Fujishita, H. Sugimoto, T. Endo, H. Murai, D.R. Davies, Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13040-13043.
83. A.S. Espeseth, P. Felock, A. Wolfe, M. Witmer, J. Grobler, N. Anthony, M. Egbertson, J.Y. Melamed, S. Young, T. Hamill, J.L. Cole, D.J. Hazuda, HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11244-11249.
84. M. Sechi, M. Derudas, R. Dallocchio, A. Dessi, A. Bacchi, L. Sannia, F. Carta, M. Palomba, O. Ragab, C. Chan, R. Shoemaker, S. Sei, R. Dayam, N. Neamati, Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors, J. Med. Chem. 47 (2004) 5298-5310.
85. S. Ferro, M.L. Barreca, L. De Luca, A. Rao, A.M. Monforte, Z. Debyser, M. Witvrouw, A. Chimirri, New 4-[(1-benzyl-1H-indol-3-yl)carbonyl]-3-hydroxyfuran-2(5H)-ones, beta-diketo acid analogs as HIV-1 integrase inhibitors, Arch. Pharm. (Weinheim) 340 (2007) 292-298.
86. L. De Luca, M.L. Barreca, S. Ferro, N. Iraci, M. Michiels, F. Christ, Z. Debyser, M. Witvrouw, A. Chimirri, A refined pharmacophore model for HIV-1 integrase inhibitors: optimization of potency in the 1H-benzylindole series, Bioorg. Med. Chem. Lett. 18 (2008) 2891-2895.
87. L. De Luca, M.L. Barreca, S. Ferro, F. Christ, N. Iraci, R. Gitto, A.M. Monforte, Z. Debyser, A. Chimirri, Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75, ChemMedChem 4 (2009) 1311-1316.
88. L. De Luca, R. Gitto, F. Christ, S. Ferro, S. De Grazia, F. Morreale, Z. Debyser, A. Chimirri, 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process, Antiviral Res. 92 (2011) 102-107.
89. S. Ferro, S.D. Grazia, L. De Luca, R. Gitto, C.E. Faliti, Z. Debyzer, A. Chimirri, Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors, Molecules 16 (2011) 6858-6870.
90. L. De Luca, S. De Grazia, S. Ferro, R. Gitto, F. Christ, Z. Debyser, A. Chimirri, HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation, Eur. J. Med. Chem. 46 (2011) 756-764.
91. D. Rogolino, M. Carcelli, C. Compari, L. De Luca, S. Ferro, E. Fisicaro, G. Rispoli, N. Neamati, Z. Debyser, F. Christ, A. Chimirri, Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process, Eur. J. Med. Chem. 78 (2014) 425-430.
92. S. Ferro, L. De Luca, G. Lo Surdo, F. Morreale, F. Christ, Z. Debyser, R. Gitto, A. Chimirri, A new potential approach to block HIV-1 replication via proteinprotein interaction and strand-transfer inhibition, Bioorg. Med. Chem. 22 (2014) 2269-2279.
93. L. De Luca, S. Ferro, F. Morreale, F. Christ, Z. Debyser, A. Chimirri, R. Gitto, Fragment hopping approach directed at design of HIV IN-LEDGF/p75 interaction inhibitors, J. Enzyme Inhib. Med. Chem. 28 (2013) 1002-1009.
94. J. Anderson, C. Schiffer, S.K. Lee, R. Swanstrom, Viral protease inhibitors, Handb. Exp. Pharmacol. 189 (2009) 85-110.
95. O.P. Flint, M.A. Noor, P.W. Hruz, P.B. Hylemon, K. Yarasheski, D.P. Kotler, R.A. Parker, A. Bellamine, The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications, Toxicol. Pathol. 37 (2009) 65-77.
96. H.Y. Wei, C.S. Lu, T.H. Lin, Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques, J. Mol. Graph. Model. 26 (2008) 1131-1144.
97. N.S. Ismail, R.S. El Dine, M. Hattori, K. Takahashi, M. Ihara, Computer based design, synthesis and biological evaluation of novel indole derivatives as HCV NS3-4A serine protease inhibitors, Bioorg. Med. Chem. 16 (2008) 7877-7887.
98. A. Gopalsamy, M. Shi, G. Ciszewski, K. Park, J.W. Ellingboe, M. Orlowski, B. Feld, A.Y. Howe, Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase, Bioorg. Med. Chem. Lett. 16 (2006) 2532-2534.
99. M.Z. Zhang, Y. Wang, P. Paueksakon, R.C. Harris, Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy, Diabetes 63 (2014) 2063-2072.
100. G. Lampis, D. Deidda, C. Maullu, M.A. Madeddu, R. Pompei, F. Delle Monachie, G. Satta, Sattabacins and sattazolins: new biologically active compounds with antiviral properties extracted from a Bacillus sp, J. Antibiot. (Tokyo) 48 (1995) 967-972.
101. K.M. Snyder, T.S. Doty, S.P. Heins, A.L. DeSouchet, K.A. Miller, Asymmetric total synthesis of (+)-sattazolin, Tetrahedron Lett. 54 (2013) 192-194.
102. P.W. Hsieh, F.R. Chang, K.H. Lee, T.L. Hwang, S.M. Chang, Y.C. Wu, A new anti-HIV alkaloid, drymaritin, and a new C-glycoside flavonoid, diandraflavone, from Drymaria diandra, J. Nat. Prod. 67 (2004) 1175-1177.
103. A.M.V. Pinto, J.P.G. Leite, W.J. Ferreira, D.N. Cavalcanti, R.C. Villca, V. Giongo, V.L. Teixeira, I.C.N.D.P. Paix~ao, Marine natural seaweed products as potential antiviral drugs against Bovine viral diarrhea virus, Br. J. Pharm. 22 (2012) 813-817.
104. M. Chen, L. Gan, S. Lin, X. Wang, L. Li, Y. Li, C. Zhu, Y. Wang, B. Jiang, J. Jiang, Y. Yang, J. Shi, Alkaloids from the root of Isatis indigotica, J. Nat. Prod. 75 (2012) 1167-1176.
105. P. Bag, D. Ojha, H. Mukherjee, U.C. Halder, S. Mondal, A. Biswas, A. Sharon, L. Van Kaer, S. Chakrabarty, G. Das, D. Mitra, D. Chattopadhyay, A dihydropyrido-indole potently inhibits HSV-1 infection by interfering the viral immediate early transcriptional events, Antiviral Res. 105 (2014) 126-134.
106. A.K. Karuppannan, K.X. Wu, J. Qiang, J.J. Chu, J. Kwang, Natural compounds inhibiting the replication of Porcine reproductive and respiratory syndrome virus, Antiviral Res. 94 (2012) 188-194.
107. N.K. Garg, R. Sarpong, B.M. Stoltz, The first total synthesis of dragmacidin d, J. Am. Chem. Soc. 124 (2002) 13179-13184.
108. Adele Cutignano, Giuseppe Bifulco, Ines Bruno, Agostino Casapullo, Luigi Gomez-Paloma, R. Riccio, Dragmacidin F: a new antiviral bromoindole alkaloid from the Mediterranean sponge Halicortex sp, Tetrahedron 56 (2000) 3743-3748.
109. X. Zhou, J. Liu, B. Yang, X. Lin, X.W. Yang, Y. Liu, Marine natural products with anti-HIV activities in the last decade, Curr. Med. Chem. 20 (2013) 953-973.
110. L. Gupta, A. Talwar, P.M. Chauhan, Bis and tris indole alkaloids from marine organisms: new leads for drug discovery, Curr. Med. Chem. 14 (2007) 1789-1803.
111. C.J. Tan, Y.T. Di, Y.H. Wang, Y. Zhang, Y.K. Si, Q. Zhang, S. Gao, X.J. Hu, X. Fang, S.F. Li, X.J. Hao, Three new indole alkaloids from Trigonostemon lii, Org. Lett. 12 (2010) 2370-2373.
112. K. Takada, H. Kajiwara, N. Imamura, Oridamycins A and B, anti-Saprolegnia parasitica indolosesquiterpenes isolated from Streptomyces sp. KS84, J. Nat. Prod. 73 (2010) 698-701.
113. L. Ding, J. Munch, H. Goerls, A. Maier, H.H. Fiebig, W.H. Lin, C. Hertweck, Xiamycin, a pentacyclic indolosesquiterpene with selective anti-HIV activity from a bacterial mangrove endophyte, Bioorg. Med. Chem. Lett. 20 (2010) 6685-6687.
114. L. Ding, A. Maier, H.H. Fiebig, W.H. Lin, C. Hertweck, A family of multicyclic indolosesquiterpenes from a bacterial endophyte, Org. Biomol. Chem. 9 (2011) 4029-4031.
115. Z. Xu, M. Baunach, L. Ding, C. Hertweck, Bacterial synthesis of diverse indole terpene alkaloids by an unparalleled cyclization sequence, Angew. Chem. Int. Ed. 51 (2012) 10293-10297.
116. J. Peng, T. Lin, W. Wang, Z. Xin, T. Zhu, Q. Gu, D. Li, Antiviral alkaloids produced by the mangrove-derived fungus Cladosporium sp. PJX-41, J. Nat. Prod. 76 (2013) 1133-1140.
117. W. Gul, M.T. Hamann, Indole alkaloid marine natural products: an established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases, Life Sci. 78 (2005) 442-453.
118. J.P. Singh, S. Tamang, P.R. Rajamohanan, N.C. Jima, G. Chakraborty, G.C. Kundu, S.M. Gaikwad, M.I. Khan, Isolation, structure, and functional elucidation of a modified pentapeptide, cysteine protease inhibitor (CPI- 2081) from Streptomyces species 2081 that exhibit inhibitory effect on cancer cell migration, J. Med. Chem. 53 (2010) 5121-5128.
119. A.M. Heapy, A.V. Patterson, J.B. Smaill, S.M. Jamieson, C.P. Guise, J. Sperry, P.A. Hume, K. Rathwell, M.A. Brimble, Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions, Bioorg. Med. Chem. 21 (2013) 7971-7980.
120. X. Yu, D. Sun, Macrocyclic drugs and synthetic methodologies toward macrocycles, Molecules 18 (2013) 6230-6268.
121. E.M. Driggers, S.P. Hale, J. Lee, N.K. Terrett, The exploration of macrocycles for drug discoveryean underexploited structural class, Nat. Rev. Drug Discov. 7 (2008) 608-624.
122. J. Mallinson, I. Collins, Macrocycles in new drug discovery, Future Med. Chem. 4 (2012) 1409-1438.
123. D. Krahn, C. Ottmann, M. Kaiser, Macrocyclic proteasome inhibitors, Curr. Med. Chem. 18 (2011) 5052-5060.
124. J.W. Blunt, B.R. Copp, M.H. Munro, P.T. Northcote, M.R. Prinsep, Marine natural products, Nat. Prod. Rep. 22 (2005) 15-61.
125. M. Somei, F. Yamada, Simple indole alkaloids and those with a nonrearranged monoterpenoid unit, Nat. Prod. Rep. 22 (2005) 73-103.